Clinical Trials Logo

Filter by:
NCT ID: NCT04706247 Completed - Pain Clinical Trials

Thoracic Combined Spinal Epidural Anesthesia for Breast Surgery

Start date: January 4, 2021
Phase:
Study type: Observational

The aim of the study is to investigate the efficacy of the thoracic combined spinal epidural anesthesia in breast surgery.

NCT ID: NCT04706104 Completed - Long QT Syndrome Clinical Trials

QT Measurement Techniques and Anesthesia Management

Start date: October 10, 2020
Phase:
Study type: Observational

In studies, the effects of drugs used for anesthesia and analgesia on QT distance were evaluated in isolation. However, drugs are administered in combination with each other during anesthesia induction. Therefore, drugs interact in terms of positive and undesirable effects. In addition, most of the studies examining anesthesia and QT distance have been conducted in non-cardiac surgery. The target group in this study is the adult patient group who will undergo cardiac surgery. The primary aim of our study is to investigate the effect of two different types of anesthesia induction techniques on QT distance in patients undergoing open-heart surgery. QT evaluation will be performed after endotracheal intubation after anesthesia induction.

NCT ID: NCT04706000 Completed - Endometrial Polyp Clinical Trials

Autophagy Markers in Endometrial Polyps

Start date: January 8, 2021
Phase:
Study type: Observational

The aim of this research is to evaluate autophagy markers in patients with endometrial polyps

NCT ID: NCT04705961 Completed - Clinical trials for Surgery--Complications

Bile Leakage Test in Emergency Hydatid Liver Cyst Surgery Case Report

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

In liver cyst hydatid surgery, presence of cysto-biliary communication (CBC) is important for the prevention of postoperative morbidity. If cysto-biliary connections are not obvious, diagnosis is not easy. Intraoperative bile leakage test has been shown to reduce postoperative biliary complications by revealing occult CBCs. However, bile leakage testing in emergency conditions such as hydatid cyst perforation has not been experienced so far.

NCT ID: NCT04705675 Completed - Breastfeeding Clinical Trials

The Impact of Breastfeeding Education on Breastfeeding Behavior and the Use of Traditional Practices

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

H1a: The breastfeeding education has an effect the behaviors of mothers toward breastfeeding. H1b: The breastfeeding education has an effect on the use of traditional breastfeeding practices. H0a: The breastfeeding education has not an effect the behaviors of mothers toward breastfeeding. H0b: The breastfeeding education has not an effect on the use of traditional breastfeeding practices.

NCT ID: NCT04705389 Not yet recruiting - Clinical trials for Merkel Cell Carcinoma

SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines

SUMMERTIME
Start date: September 2021
Phase: N/A
Study type: Interventional

Merkel cell carcinoma (MCC) is a rare aggressive skin carcinoma. Approximately 80% of MCC are related to the Merkel Cell Polyomavirus (MCPyV). Although rates of relapse are high, the follow-up strategy lacks consensus. Patients are usually assessed clinically every 3 to 6 months for the first 2-3 years, and every 6 to 12 months thereafter. In the European guidelines, patients with early stages are monitored with clinical examination and ultrasonography of lymph nodes, while whole-body imaging is optional in patients with stage III disease, on a yearly basis for 5 years. Such strategy may prevent the diagnosis of infra-clinical recurrences, whereas patients could still be treated with surgery or radiation therapy. Until 2017, patients with advanced disease were treated with chemotherapies, with no long-term benefit. Immunotherapies with PD-1/PD-L1 inhibitors currently allow durable responses in 50% of such patients. This major change in the management of MCC patients argues for a follow-up strategy that would allow early diagnosis of infra-clinical metastases, when tumoral burden is still low. Given that all patients cannot be monitored by systematic regular imaging, additional non-invasive tools are needed. Blood-based biomarkers as a surrogate of tumor burden are advantageous as they can be repeated over time, providing guidance on when imaging is necessary. The study aims to assess two blood biomarkers, MCPyV T-Ag antibodies and cell-free miR-375, in a prospective fashion from baseline diagnosis, in a cohort of 150 European MCC patients

NCT ID: NCT04704934 Recruiting - Clinical trials for Gastroesophageal Junction Adenocarcinoma

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Start date: May 21, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.

NCT ID: NCT04704752 Completed - Clinical trials for Eosinophilic Esophagitis

Swallowing Characteristics of Pediatric Patients With Eosinophilic Esophagitis

Start date: May 25, 2020
Phase:
Study type: Observational [Patient Registry]

Eosinophilic Esophagitis (EoE) can affect patients all age group and clinical symptoms of the disease varies depending on the patient's ages. Infants and toddlers with EoE generally have food refusal, vomiting and poor weight gain. Older school-aged children and adolescents may have abdominal and chest pain, difficulty in swallowing (dysphagia) especially in solid foods. In the meantime, many children especially infants and toddlers, are not perceptive of their dysphagia, because they have the ability to compensate. Such as, avoiding certain textures or increases liquid intake in the meal.To date, to our knowledge, there is no study in the literature has investigated complex swallowing behaviour (including all phases), oral-motor evaluation and/or swallowing safety. Thus, the present study purposed to investigate (a) descriptive and clinical swallowing characteristics of children with EoE (b) the relation between disease characteristic and swallowing function.

NCT ID: NCT04704570 Completed - Healthy People Clinical Trials

Remote Exercise Programs and Preventive Training in Asymptomatic Individuals

Start date: April 14, 2021
Phase: N/A
Study type: Interventional

In recent years, it has been emphasized that preventive approaches are a less costly and more effective way to treat a pathology. Primary preventive approaches should become widespread, especially in problems with changeable risk factors such as spine health. Various preventive approaches and exercise training seem to be an effective way to prevent the development of back and neck pain. Again, in recent years, the pandemic process has increased the interest and need for tele-rehabilitation. As a result, scientific research results on tele-rehabilitation are needed as a necessity to adapt to the Covid-19 epidemic and the globalizing world. The aim of the thesis study planned in this context is to investigate the effectiveness of remote exercise applications on lumbar and cervical region muscle architecture and functionality in asymptomatic individuals.Another aim of this study is to investigate the remote applicability of functional level, quality of life, kinesophobia and cognitive assessment.

NCT ID: NCT04704219 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

KEYNOTE-B61
Start date: February 23, 2021
Phase: Phase 2
Study type: Interventional

This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.